Antaros Medical
Antaros Medical is recorded as a service provider in 8 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 8 of 8 trials · Latest update first
A Phase 2b, Double-Blind Study to Investigate the Effect of LY3437943 on Renal Function in Participants with Overweight or Obesity and Chronic Kidney Disease with or without Type 2 Diabetes
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
Efficacy and safety of cagrilintide for weight management in participants with overweight or obesity
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
J2A-MC-GZPL: A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION); J2A-MC-GZL1: Participants with Hypertension and Obesity or Overweight; J2A-MC-GZL2: Participants with Hypertension and Obesity or Overweight
Sponsor Eli Lilly & Co.
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Sponsor 89bio Inc.
- Start (EU)
- Latest update
- Estimated end
Efficacy and safety of cagrilintide for weight management in participants with overweight or obesity and type 2 diabetes
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Compensated Cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Sponsor 89bio Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Severe Hypertriglyceridemia (SHTG)
Sponsor 89bio Inc.
- Start (EU)
- Latest update
- Estimated end
Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) s.c. in doses 2.4 mg/2.4 mg and 1.0 mg/1.0 mg once weekly versus placebo in participants with type 2 diabetes inadequately controlled on diet and exercise.
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Antaros Medical?
The 2026-10-09 snapshot links Antaros Medical to 8 distinct CTIS trials. Recorded services include MRI central reading, Imaging, imaging supplier, Laboratory services, among 5 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Antaros Medical?
The most frequently recorded therapeutic areas are Endocrinology, Metabolic Disorders, Nephrology. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Antaros Medical conducted?
The linked trials record locations in 17 countries, including Italy, Poland, Germany, Spain, Czechia. These are trial locations, not confirmed office locations or countries where Antaros Medical delivered services.
What can this page tell me about Antaros Medical's trial experience?
Browse 8 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Antaros Medical. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Antaros Medical AB